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vancomycin US$3909.2, daptomycin US$6131.2 and tigecycline US$5509.0. The 
treatment with linezolid was associated with a shorter stay in the intensive care 
unit (7 days on average) which reduces the cost of treatment because it allowed 
the switch from intravenous to oral administration (5 days on average). Results 
for each alternative in QALYs were: linezolid 0.063, vancomycin 0.060, 
daptomycin 0.061 and tigecycline 0.059. The results for each alternative in terms 
of percentage of patients cured were: linezolid 84.4%, vancomycin 74.7%, 
daptomycin 78.1% and tigecycline 70.4%. The model results indicate that 
linezolid is dominant compared to vancomycin, daptomycin and tigecycline. 
Probabilistic sensitivity analyses showed the robustness of these findings. 
CONCLUSIONS: Linezolid is a cost-saving alternative in the treatment of cSSTI in 
the Chilean National Fund of Health (FONASA).  
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COST-EFFECTIVENESS EVALUATION OF LINEZOLID, VANCOMYCIN AND 
TEICOPLANIN IN TREATING NOSOCOMIAL PNEUMONIA CAUSED BY 
METHICILIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) – PRIVATE 
HEALTH CARE SYSTEM PERSPECTIVE  
Fujii RK1, Hájek P2, Lanzara GDA1, Manfrin DF1, Mould J3 
1Pfizer, Inc., São Paulo, Brazil, 2Pfizer, Praha, Czech Republic, 3Pfizer, New York, NY, USA  
OBJECTIVES: The objective of this research is to evaluate the cost-effectiveness 
of linezolid 600mgBID(LI), vancomycin 1gBID(VA) and teicoplanin 400mgBID(TE) 
in the treatment of nosocomial pneumonia caused by MRSA under the private 
health care system perspective. METHODS: To compare the options, a decision 
tree model was built considering an arm per treatment option, from which 
patients could respond to the initial treatment and continue to maintenance 
treatment using the same antibiotics, or do not respond, and repeat the 
treatment with assumed 50% chance to use one of the other two antibiotics. 
Clinical or microbiological effectiveness could be used as determinants of 
response. Effectiveness measures were mortality, clinical and microbiological 
responses, calculated by an indirect comparison of a literature systematic 
review. Hospitalization days were evaluated. Only direct costs were considered, 
and were obtained from CBHPM2010 for medical procedures, CMED 
December2012, considering X-factory price plus 18% tax for medications  
and BRASINDICE December2012 for materials. Values were represented in 
2012USD. A time horizon of 1 year was considered. RESULTS: Clinical response 
rates were 66.5%(VA), 68.3%(TE), 72.6%(LI), microbiological response rates were 
56.1%(VA), 55.9%(TE), 64.4%(LI), mortality rates were 15.74%(VA), 13.56%(TE), 
10.13%(LI). If clinical response was considered as a determinant of success, the 
treatment costs would be US$33,190.76(VA), US$41,657.71(TE), US$27,036.62(LI), 
hospitalization days would be 41(VA), 39(TE), 26(LI), and if microbiological 
response was considered, the treatment costs would be US$34,597.12(VA); 
US$42,574.61(TE), US$28,514.48(LI) and hospitalization days would be 42(VA), 
40(TE), 28(LI). Incremental cost-effectiveness ratios for TE and LI when compared 
to VA for clinical response were US$470,386.13, -US$100,887.50(dominant),  
and for microbiological response were -US$398,874.67(dominated),  
-US$73,284.78(dominant) respectively. CONCLUSIONS: Compared to 
vancomycin, teicoplanin was either dominated or did not reach cost-
effectiveness considering a willingness to pay of US$32,621.93 (3xBrazilian GDP 
per capita), whereas linezolid was dominant, presenting lower mortality while 
offsetting costs, mainly driven by less hospitalization days at private health care 
services.  
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COST-EFFECTIVENESS EVALUATION OF AMPHOTERICIN B, AMPHOTERICIN B 
LIPOSOMAL, CASPOFUNGIN AND VORICONAZOL IN TREATING ASPERGILLOSIS 
UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE  
Fujii RK1, Manfrin DF1, Lanzara GDA1, Hájek P2, Mould J3 
1Pfizer, Inc., São Paulo, Brazil, 2Pfizer, Praha, Czech Republic, 3Pfizer, New York, NY, USA  
OBJECTIVES: Aspergillosis is the second cause of invasive fungal infections with 
high mortality rates. The objective of this research is to evaluate the cost-
effectiveness of amphotericin B(AB) 1.5mg/kg/day, amphotericin B liposomal(AL) 
3mg/kg/day, caspofungin(CA) 50mg/day, voriconazol 8mg/kg/day(VO) including 
maintenance oral Voriconazol 400mg/day scheme in the treatment of 
aspergillosis under the Brazilian public health care system perspective. 
METHODS: To compare the options, a decision tree model was built considering 
sequential treatments, from which patients could respond to one initial 
treatment and continue to a maintenance phase of the same medication, or do 
not respond due to either inefficacy or adverse events and switch treatments 
with assumed equal chance to use one of the other options. Effectiveness 
measures were mortality, clinical response and days of hospitalization, 
calculated by indirect comparison of a literature systematic review. Only direct 
costs were considered, and were obtained from the publicly available databases 
of DATASUS. Values were represented in 2012USD. A time horizon no longer 
than 4 weeks was considered, thus discounting was not applied. One-way 
sensitivity analysis considered de-hospitalization in maintenance phases while 
using oral Voriconazol. RESULTS: Clinical response rates were 36.40%(AB), 
34.60%(AL), 34.20%(CA), 56.67%(VO), mortality rates were 50.90%(AB), 48.70%(AL), 
44.70%(CA), 34.10%(VO) and hospitalization days were 26.35(AB), 24.68(AL), 
25.33(CA), 22.55(VO). Expected treatment costs were 18,380.91USD(AB), 
53,076.12USD(AL), 27,145.04USD(CA) and 24,510.88USD(VO). Considering AB as 
the baseline for cost-effectiveness, VO presented an incremental cost-
effectiveness ratio(ICER) of 30,241.60 while other options were dominated with 
higher costs and lower effectiveness. If de-hospitalization was considered, VO 
arm would sum 14.62 hospitalization days, treatment cost of 23,299.90USD and 
an ICER of 24,267.34USD. CONCLUSIONS: Assuming a willingness to pay of 
32,621.93USD (3 times Brazilian 2011GDP per capita), VO was the only cost-
effective option compared to AB, additionally presenting lower mortality and less 
hospitalization days while allowing early de-hospitalization at public health care 
services.  
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ECONOMIC EVALUATIONS OF ANTIRETROVIRAL THERAPY MONITORING USING 
ROUTINE HIV VIRAL LOAD TESTING IN LOW-INCOME SETTINGS: A 
SYSTEMATIC REVIEW  
Mann M, Babigumira JB 
University of Washington, Seattle, WA, USA  
OBJECTIVES: Strategies for monitoring antiretroviral therapy (ART) include 
clinical assessment, CD4 testing, and viral load (VL) testing. Although benefits of 
VL monitoring have been established, it is considered too expensive to 
implement in low-income settings. Several studies have found varying levels of 
cost-effectiveness (CE) of VL monitoring. We reviewed the studies and evaluated 
their quality to identify gaps in evidence of potential CE of VL testing in low-
income settings. METHODS: We performed a systematic review of studies with a 
cost analysis using a Medline search from 1980-2012 with keywords ‘cost’, 
‘economic’, ‘viral load’, and ‘HIV’. We assessed study quality using the validated 
Quality of Health Economic Scales (QHES) questionnaire and the Drummond 
criteria. RESULTS: We identified and included eight studies. QHES scores ranged 
from 44 to 83 (on a scale of 0-100). Two methodologically strong studies used 
Markov models, and three used high quality cohort data. One study was 
performed among children, one used clinical trial data that may not be 
generalizable, and one did not include a CD4 monitoring strategy. Incremental 
CE ratios ranged from $86/life-year to $68,698/quality-adjusted life-year and were 
most sensitive to cost of VL test kits, followed by treatment failure rates and 
utilities. Two studies found VL testing to be CE (<3 times gross domestic product 
(GDP)/capita), and three found it to be highly CE (<1 times GDP/capita). Only one 
study included a societal perspective, which found VL monitoring to be cost 
saving. CONCLUSIONS: This evidence suggests that VL testing may be CE in low-
income settings. The five studies that were methodologically strong and utilized 
high quality data found VL monitoring CE or highly CE. Reduced costs of VL test 
kits may further enhance CE. Future studies are needed to address 
methodological and data quality issues as well as use of a societal perspective.  
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GEMIFLOXACIN AS FIRST LINE TREATMENT FOR COMMUNITY ACQUIRED 
PNEUMONIA IN MEXICO: A COST—EFFECTIVENESS STUDY  
Galindo-Suárez RM1, Salinas-Escudero G2, Muciño-Ortega E1 
1Pfizer S.A. de C.V., Mexico City, Mexico, 2Hospital Infantil de México Federico Gómez, Secretaría 
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OBJECTIVES: Community acquired pneumonia (CAP) still represents an 
important disease in Mexico. The study of both economic and clinical outcomes 
of treatments remains relevant. The aim of this study was to assess the 
consequences of the use of antibiotics to treat CAP, from the perspective of 
Instituto Mexicano del Seguro Social (IMSS). METHODS: A decision tree model 
that considers clinical success and failure either whit first and second line 
treatments, presentation or not of adverse events (AE´s), as well as death was 
developed. The antibiotics considered in the assessment were: clarithromycin 
(1,000 mg/day), levofloxacin (1,000 mg/day), ceftriaxone (1,000 mg/day), 
cefuroxime (1,500 mg/day), moxifloxacin (400 mg/day) and gemifloxacin (320 
mg/day). The last option is not listed in IMSS formulary. Clinical data were 
extracted from international literature. Effectiveness measures were clinical 
success rate and length of stay (LOS). The model considered direct medical costs 
(2012 US$): drugs, diagnostic tests, physician visits, LOS, emergency room and 
intensive care unit; cost were extracted from institutional sources. Resource use 
for CAP was extracted from clinical files (n=94 adult patients) treated at one IMSS 
hospital, whereas resource use for AE´s treatment was obtained through expert 
opinion (panel). One-way sensitivity analysis and acceptability curves were 
performed. RESULTS: The alternative that presented the most favorable 
pharmacoeconomic profile was gemifloxacin ($3237 per patient, 95.3% of success 
rate and 6.22 days of LOS), followed by levofloxacin and clarithromycin, with 
marginal differences in clinical success but around $1600 of incremental cost. 
The alternative with the less favorable profile was moxifloxacin: $1784.52 of 
incremental cost, -8.8% of clinical success and +6.6 days of LOS regarding 
gemifloxacin. The results were robust to +10% acquisition cost and +5% AE´s 
incidence for gemifloxacin. CONCLUSIONS: Alternatives with potential to 
promote savings in the management of CAP (like gemifloxacin) are valuable, 
which becomes more relevant in contexts with limited resources.  
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POTENTIAL BENEFITS ANALYSIS OF QUADRIVALENT INFLUENZA VACCINE 
(QIV) ON INFLUENZA DISEASE BURDEN IN THE UNITED KINGDOM, YEAR BY 
YEAR ANALYSIS (2000-2010)  
Meier G1, Van Bellinghen LA2, Van Vlaenderen I2 
1GlaxoSmithKline Vaccines, King of Prussia, PA, USA, 2CHESS, Ternat, Belgium  
OBJECTIVES: Benefits of QIV over trivalent inactivated vaccine (TIV) are 
dependent on the proportion of influenza circulation attributable to influenza-B 
and the extent of vaccine matching with respect to circulating B-lineages. 
Applying the 2000-2010 influenza data from the Health Protection Agency, the 
impact of vaccination with QIV versus TIV on influenza morbidity and mortality 
in the UK was evaluated to estimate potential benefits of QIV if it had been 
available during this time. METHODS: Using current influenza management 
guidance (vaccination of those at-risk and the elderly), a multi-cohort, static, 1-
year decision model was used. Influenza A and B was accounted for separately. 
Vaccine efficacy data was derived from Cochrane Databases (TIV) and meta-
analyses (QIV). The model considers the perspective of the UK National Health 
Service. RESULTS: Using the average influenza-B circulation and vaccine 
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matching data over 2000-2010, 17,088 additional cases, 337 additional 
hospitalizations and 168 additional deaths could potentially be avoided annually 
with QIV versus TIV. There would be no additional benefits for well-matched 
years 2000-03 and 2009-10. In mismatched years benefits could range from 
minor, such as 2003-4 (100% mismatched, 0.4% influenza-B circulation) where 
578 additional cases, 11 additional hospitalizations and 6 additional deaths 
potentially avoided to significant impact, such as 2005-6 (98.8% mismatched, 70% 
influenza-B circulation) with 100,296 additional cases, 1,976 additional 
hospitalizations and 988 additional deaths potentially avoided. CONCLUSIONS: 
Our analysis predicts that using recent influenza-B circulation and vaccine 
matching data, in 6 out of 10 years, a strategy of vaccination with QIV would 
have been more effective than TIV in reducing the number of influenza cases, 
and associated hospitalisations and deaths. Retrospective analysis of influenza 
circulation suggests that co-circulation of influenza-B lineages persists and that 
mismatch is frequent and unpredictable. The use of QIV might aid in reducing 
the associated burden of mismatched influenza-B.  
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OBJECTIVES: Meningococcal disease (MD) is a serious public health problem 
worldwide. It mainly affects low-income countries with higher impact in the 
‘meningococcal belt’ located at the African Sub Sahara. Children younger than 5 
years old are the most affected age group, with the highest incidence in the first 
year of life. Our aim is to evaluate the cost-effectiveness of the introduction of 
routine vaccination with a tetravalent meningococcal conjugate vaccine (MCV-4) 
in the Colombian EPI. METHODS: An age-dependent Markov model, which 
followed a cohort of children under one year of age up to their life expectancy, 
was developed. Parameters of occurrence and care costs were based on data 
from National Surveillance System, official data sources, and literature review. 
Serotype coverage was taken from SIREVA NM Colombia surveillances from 2007 
to 2010. A 3 + 1 schedule and a vaccination price of US$ 30.00 per dose were 
assumed in the base case, compared against no vaccination (only treatment the 
disease). All cost are expressed in 2011 US dollars. RESULTS: Introduction of 
MCV-4 would avoid 34 cases of meningococcal meningitis (MM), 27 cases of 
meningococcal sepsis, and 10 deaths in the lifespan of each infant’s cohort 
evaluated. MCV-4 vaccination avoids 126 years of life (LY), or 165 disability 
adjusted life years (DALYs). Vaccination would costs raises to US$ 71 million. The 
ICER of vaccination strategy compared to no vaccination was estimated at US$ 
441,998, which is very higher than the Colombian GPD (US$ 6,883). 
CONCLUSIONS: Routine vaccination against Neisseria meningitides with MCV-4in 
Colombia would not be cost-effective with tetravalent conjugate vaccine in the 
base case analysis.  
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COST EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT (PCV13) 
AND 23-VALENT (PPSV23) PNEUMOCOCCAL VACCINES FOR ADULTS IN A 
PRIVATE COLOMBIAN INSTITUTION  
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OBJECTIVES: Streptococcus pneumoniae causes significant morbidity and 
mortality worldwide in both children and adults. The aim of this analysis is to 
evaluate the cost-effectiveness of vaccinating colombian population over 50 
years with 13-valent pneumococcal conjugated vaccine (PCV 13) from the 
institutional perspective in Colombia. METHODS: A Markov model was adapted 
to Colombian settings, using a time horizon of 5 years (3% annual discount rate). 
Comparators were PCV13, PPSV23 and no vaccination, vaccine coverage was 70%. 
Population size over 50 years of a Colombian insurance institution (n: 775,301) 
adjusted according with Colombian data was included, transition probabilities 
were extracted from a literature review, medical costs were taken from a local 
study developed by the “Fundación Cardio Infantil”, vaccines costs were taken 
from local report (SISMED), the diseases incidence was retrieved from literature 
(Castañeda et al. 2010, Dickinson et al 2001), vaccines efficacies were taken from 
literature (for PCV13 children data from PCV7 studies were adjusted by 
immunosenescence) and costs are expressed in 2012 US$. Effectiveness 
measures were the number of pneumococcal diseases and deaths prevented, as 
well as life years (LY) gained saved. Probabilistic sensitivity analyses were 
performed. RESULTS: Over a 5-year period, vaccinating with PCV13 prevents 
1,427 cases of invasive pneumococcal disease compared to PPSV23 and 1847 
compared no vaccination; 1691 and 1470 cases of invasive pneumonia and 188 
and 256 deaths, respectively. PCV13 saves 101,564 LY’s compared to PPSV23 and 
92,261 LY’s compared to no vaccination. Total expected costs (vaccination + 
medical costs) were US$164.0M for PCV13, US$ 164.4 PPSV23 and US$155.0M for 
no vaccination. CONCLUSIONS: Vaccinating adults over 50 years with PCV13 in a 
Colombian insurance institution is a cost-saving alternative in comparison to 
PPSV23 and a cost-effectiveness alternative to no vaccination (ICER = US$ 96.6 
/LY).  
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AND 23-VALENT (PPSV23) PNEUMOCOCCAL VACCINES FOR ADULTS IN 
BOGOTA, COLOMBIA – PUBLIC SCENARIO  
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OBJECTIVES: Streptococcus pneumoniae causes significant morbidity and 
mortality worldwide in both children and adults. The aim of this analysis is to 
evaluate the cost-effectiveness of vaccinating the Bogota adult citizens (over 50 
years) with 13-valent pneumococcal conjugated vaccine (PCV 13) versus 23-
valent pneumococcal polysaccharide vaccine (PPSV23) and no vaccination from 
the public payer’s perspective in Colombia. METHODS: A Markov model was 
adapted to the Colombian public setting, using a time horizon of 4 years (3% 
annual discount rate). Comparators were PCV13, PPSV23 and no vaccination, 
vaccine coverage of 70% and projected Colombian population for 2013 were 
assumed, transition probabilities were extracted from literature review, medical 
costs were taken from a local study developed by the “Fundacion CardioInfantil”; 
vaccine prices were taken from the PAHO revolving fund price list, vaccines 
efficacies were taken from literature (for PCV13 children data from PCV7 studies 
were adjusted by immunosenescence), diseases incidences were retrieved from 
literature (Castañeda et al. 2010, Dickinson et al 2001) and costs were expressed 
in 2012 US$. Effectiveness measures were the number of pneumococcal diseases 
and deaths prevented, as well as life years (LY) saved. RESULTS: Over a 4-year 
period, vaccinating with PCV13 and PPSV23 against no vaccination prevents 2587 
and 1804 cases of invasive pneumococcal disease; 2365 and 11 cases of invasive 
pneumonia and 357 and 139 deaths respectively. PCV13 saves 518 LY’s compared 
to PPSV23 and 44.9 LY’s compared to no vaccination. Total expected saving 
(vaccination + medical costs) for PCV13 was US$5.8M against PPSV23 and US$3.2 
against no vaccination (total expected costs: US$54.5M; US$60.3M and US$57.7M 
respectively). CONCLUSIONS: Vaccinating adults over 50 years with PCV13 in 
Bogota is a cost-saving alternative in comparison to PPSV23 and no vaccination 
(US$3.5 and US$1.9 savings per patient, respectively). Study findings could 
support the decision-making process in favor of PCV13.  
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COST-EFFECTIVENESS ANALYSIS OF PNEUMOCOCCAL CONJUGATE 
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OBJECTIVES: To evaluate the cost-effectiveness results of introducing PCV7 into 
City Immunization Programs in 7 urban China. METHODS: Six health status 
contained pneumococcal meningitis (inpatient), pneumococcal septicemia 
(inpatient), pneumonia (all-cause, inpatient), pneumonia (all-cause, outpatient), 
mild otitis media (all-cause, outpatient) and sever otitis media (all-cause, 
outpatient )were considered. Age-specific cost was collected from electronic 
patient records (2010) from 14 hospitals in 7 cities in China. Two hospitals in 
each city was selected (1 Children’s Hospital, 1 Comprehensive Hospitals) and 7 
field cities including Beijing, Guangzhou, Shenzhen, Wuhan, Xi’an, Chengdu and 
Shenyang were enrolled. Direct medical cost included registry fee, medications, 
diagnostic tests fee, and hospitalization expenditure. A discount rate of 5% was 
applied. One-way sensitivity analyses were performed to evaluate the sensitivity 
of the results to data inputs. RESULTS:   As Category II vaccinePCV7 was not cost 
effective due to the private market unit price and low penetration rate. However, 
vaccination of children under 2 years old from 7 urban China in a CIP is 
estimated to prevent 366,337 cases from infection and 3,415 cases from death 
compared to no vaccination. From a payer perspective, a PCV7 CIP had an ICER of 
RMB17, 977/QALY in Beijing, RMB79,180/ QALY in Chengdu, RMB72,406/QALY in 
Guangzhou, RMB70,896/QALY in Shenyang,RMB69,792/QALY in Shenzhen, 
RMB64,152/QALY in Wuhan and RMB76,864/ QALY in Xian. CONCLUSIONS: The 
empirical results show that under the current situation with a 860 Yuan/ dose 
vaccination price and a 85% vaccination rate, when take PCV7 into the city 
immunization plan, the spending of the cost is worth in Beijing, Guangzhou and 
Shenzhen and is acceptable in Wuhan, Shenyang, Chengdu and Xi’an.  
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OBJECTIVES: Trivalent influenza vaccines contain two influenza A and one 
influenza B strains. The Food and Drug Administration has approved live 
attenuated and inactivated quadrivalent vaccines (containing two influenza A 
and both influenza B strains). Our aim was to compare the cost-effectiveness of 
vaccination with quadrivalent versus trivalent seasonal influenza vaccines. 
METHODS: A dynamic transmission model was used to estimate the age 
stratified temporal trend in influenza virus infection incidence. The population 
was divided into 5 subgroups: Susceptible, Exposed, Infectious, Recovered, and 
Vaccinated. We estimated health service resource utilisation from published 
disease-specific probabilities of consulting a primary care physician, 
hospitalization, and death. Disease burden was expressed in clinical (health 
service utilization and death), quality of life, and economic terms. Both a payer 
and societal perspectives were adopted. We compared the costs and outcomes of 
quadrivalent vaccination with those of trivalent vaccination, assuming price 
parity between vaccines. All costs and benefits were discounted at a rate of 3% 
per annum. Probabilistic sensitivity analyses were conducted. RESULTS: Adding 
a second influenza B strain to the trivalent seasonal influenza vaccines at the 
same vaccine prices was estimated to be cost-saving in the US. Estimated mean 
annual cost savings totalled $3.9 billion (societal perspective) and $1.6 billion 
(third-party payer perspective). On average, annual clinical benefits included 
over 13.5 million averted infections, over 510,000 averted primary care 
consultations, approximately 80,000 averted hospitalizations and 5,000 deaths 
prevented. The quadrivalent vaccines dominated their trivalent equivalents, 
saving cost and generating QALY’s. All sensitivity analyses were cost-saving. 
